BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue
Bergen, 4 August 2025: Reference is made to the joint stock exchange
announcement made on 30 June 2025 by BerGenBio ASA (the "Company") and
Oncoinvent ASA ("Oncoinvent") regarding the contemplated combination of the
Company, Oncoinvent and BerGenBio Norge AS though a statutory triangular merger
(the "Merger").
An extraordinary general meeting of the Company was held on 12:00 hours (CEST)
today by electronic means through Lumi AGM. All items on the agenda were
resolved in accordance with the board of directors' and the nomination
committee's proposals, including, but not limited to, approval of the merger
plan dated 30 June 2025 (the "Merger Plan") and the fully underwritten rights
issue in the Company to raise gross proceeds of NOK 130 million.
As announced by Oncoinvent today, the Merger Plan has been approved by the
extraordinary general meeting of Oncoinvent. As a consequence, the decision to
approve the Merger will now be filed with the Norwegian Register of Business
Enterprises. Completion of the Merger remains subject to customary terms and
conditions, as further described in the Merger Plan and the joint stock exchange
announcement made on 30 June 2025.
The minutes from the extraordinary general meeting are attached hereto and will
also be made available on the Company's website www.bergenbio.no.
For further information regarding the Merger and the complete terms and
conditions for the Merger, please see the Merger Plan with appendices available
on www.bergenbio.no.
For further information, please contact:
Olav Hellebø, CEO, BerGenBio ASA, [email protected]
Rune Skeie, CFO, BerGenBio ASA, [email protected]
This information is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.